

BIOTECH Therapy



ERAP*i*

Novel inhibitors of Endoplasmic-Reticulum Aminopeptidases (ERAPs) for the treatment of psoriasis and other autoimmune diseases.

Technology matured by



- 1st ERAP2 selective inhibitors
- Several series of ERAP1 inhibitors

#Psoriasis

#Autoimmune disease

#MHC-I-opathies


Achievements :

- More than 100 analogues
- IC₅₀s from 200 nM to 4 nM
- ERAP2 potent selective inhibitors: KTGS chemistry
- Good ADME properties (on current ERAP2 lead)
- *In vivo* PoC on a psoriasis model
- ERAP-humanized animal created and available


IP status

PCT, Priority date : Dec. 18th 2020

EP, US, CA, CN, JP, IL



SIINFEKL presentation



Ex. of dose-dependent effect in a model of antigen presentation